PTHrP/MET AXIS IN THE AGGRESSIVE BEHAVIOR OF COLORECTAL CANCER CELLS

NOVOA DIAZ MARÍA BELEN; BIRKENSTOK CINTIA; CARRIERE PEDRO; GÓMEZ LUIS; GIGOLA GRACIELA; ZWENGER ARIEL; CALVO NATALIA; GENTILI CLAUDIA

Mar del Plata

Congreso; Reunión Conjunta SAIC. SAI. SAFIS 2022; 2022

Sociedad Argentina de Investigación Clínica (SAIC)

Met receptor is involved in the progression of colorectal cancer(CRC). Parathyroid hormone-related peptide (PTHrP) is a cytokinefrom the tumor and its microenvironment associated with the aggressiveness of different types of cancer. Previously, we found inHCT116 cells from CRC that the binding of PTHrP to its receptor(PTHR1) favors chemoresistance to drugs employed in CRC treatment and other events associated with an aggressive phenotype.PTHrP diminished the sensitivity of these drugs through Met. InHCT116 cells xenografts, PTHrP modulates markers expressionlinked to tumor progression including Met. The aim of this work isto further investigate the relationship between PTHR1, PTHrP andMet in CRC models. Using SU11274, the Met specific inhibitor,and the following techniques: western blot, wound healing assayand monitoring morphological changes we observed the reversalof cell migration (p